In short
Unit price is only part of the picture. Human ADM typically carries the highest unit cost; a bovine pericardium biological matrix generally costs less than human ADM (one published comparison put it ~25% lower) while offering xenograft supply security. The decision that matters for a value-analysis committee is total cost per successful reconstruction — driven as much by complication and reoperation rates as by the sticker price.
A matrix that is cheaper per unit but drives more seromas, infections or implant losses can cost more per successful reconstruction once reoperations, readmissions and extended theatre time are included. A defensible value analysis models:
Biological soft-tissue support has been associated in pooled analysis with a relative risk of 0.74 for implant removal and 0.73 for infection versus no matrix (not reaching statistical significance) — a reminder that outcome effects, not unit price, dominate the economics (Carrillo et al. 2024, Gland Surg).
| Factor | Synthetic mesh | Human / porcine ADM | Bovine pericardium matrix |
|---|---|---|---|
| Unit cost | Generally lowest | Human ADM typically highest; porcine mid | Generally lower than human ADM (~25% less in one comparison) |
| Supply model | Fully manufactured, scalable | Human ADM depends on donor tissue banks | Xenograft — scalable, not donor-dependent |
| Biological integration | No (permanent implant) | Yes (acellular scaffold) | Yes (acellular scaffold) |
| EU regulatory | CE-marked | Varies; human-derived adds tissue-donation regulation | CE-marked under EU MDR 2017/745 |
| Batch consistency | High | Human ADM variable | Batch-consistent |
Human ADM availability is tied to donor tissue supply, which can create variability and shortage risk. A bovine (xenograft) matrix is manufactured from a scalable source, supporting more predictable availability and batch-to-batch consistency — a meaningful continuity-of-service consideration for a reconstruction programme.
Run these scenarios with your own numbers using ABC’s Cost-Per-Case Calculator:
Procurement FAQ
Generally yes at the unit level: human acellular dermal matrix (ADM) is typically the most expensive soft-tissue support, and a bovine pericardium biological matrix generally costs less than human ADM. One published comparison reported an acellular bovine pericardium matrix at around 25% less expensive than ADM. Total cost per successful reconstruction, however, also depends on complication and reoperation rates, not unit price alone.
Because a matrix with a lower unit price but higher complication, reoperation or implant-loss rates can cost more per successful reconstruction once theatre time, length of stay, complication management and revision surgery are included. A defensible value analysis models total cost per case, using the institution's own audited outcome data.
Human ADM availability depends on donor tissue-bank supply, which can create variability and shortage risk. A bovine (xenograft) matrix is manufactured from a scalable source that is not dependent on human donor availability, supporting more predictable access and batch-to-batch consistency for a reconstruction programme.
Yes. Bovine pericardium matrix devices used in breast reconstruction are CE-marked under EU MDR 2017/745. Standard supplier due diligence should confirm the specific device's risk classification and current certification.
From the ExaShape® biological matrix for breast reconstruction to the EXAFAT® fat-grafting system — explore the full range of ABC devices.
Explore our productsSend us a message and our team will get back to you within 1–2 business days.